PUBLISHER: TechSci Research | PRODUCT CODE: 1938816
PUBLISHER: TechSci Research | PRODUCT CODE: 1938816
Chronic Idiopathic Constipation Therapeutic Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Route of Administration, By Distribution Channel, By Region & Competition, 2021-2031F
We offer 8 hour analyst time for an additional research. Please contact us for the details.
The Global Chronic Idiopathic Constipation Therapeutic Market is projected to expand from USD 11.53 Billion in 2025 to USD 16.46 Billion by 2031, reflecting a compound annual growth rate of 6.11%. This sector encompasses pharmaceutical agents and prescription treatments specifically developed for persistent constipation cases lacking a distinct physiological or systemic origin. Growth is primarily driven by the increasing prevalence of functional gastrointestinal disorders, an aging global population prone to reduced colonic motility, and rising healthcare investments in chronic disease management. Additionally, shifts toward sedentary lifestyles and dietary changes are enlarging the patient base needing medical attention. The International Foundation for Gastrointestinal Disorders noted in 2024 that constipation affects approximately 1 in every 6 to 7 individuals globally, highlighting the significant need for effective therapeutic solutions.
| Market Overview | |
|---|---|
| Forecast Period | 2027-2031 |
| Market Size 2025 | USD 11.53 Billion |
| Market Size 2031 | USD 16.46 Billion |
| CAGR 2026-2031 | 6.11% |
| Fastest Growing Segment | Parenteral |
| Largest Market | North America |
Despite these positive indicators, the market confronts a major obstacle regarding widespread consumer dependence on over-the-counter laxatives and dietary supplements. A substantial number of individuals experiencing symptoms opt for self-medication with affordable, accessible alternatives rather than pursuing professional medical diagnoses, a behavior that postpones the shift to advanced prescription therapies. This tendency significantly constrains the addressable audience for specialized chronic idiopathic constipation therapeutics and hinders broader revenue growth within the sector.
Market Driver
The rising global incidence of chronic idiopathic constipation, fueled by sedentary lifestyles and dietary modifications, serves as a primary engine for market expansion. As urbanization accelerates and physical activity diminishes, the prevalence of functional bowel disorders has increased, resulting in a larger patient population requiring medical care. This dynamic has led to a noticeable shift of patients moving from over-the-counter remedies to prescription-grade treatments, creating consistent demand for established therapies. Recent industry metrics reflect this trend; according to Ironwood Pharmaceuticals' Third Quarter 2025 Results released in December 2025, total prescription demand for LINZESS rose by 12% compared to the prior year.
Revenue growth is further stimulated by pharmacological innovations and the introduction of therapies with novel mechanisms of action, which offer enhanced efficacy for difficult-to-treat cases. The sector is evolving toward next-generation agents, including sodium-hydrogen exchanger 3 (NHE3) inhibitors and guanylate cyclase-C agonists, which are quickly capturing market share. This adoption is evidenced by financial performance; Ardelyx reported in its October 2025 Third Quarter Financial Results that net product sales for the novel agent IBSRELA hit $78.2 million due to increased prescriber uptake. Additionally, the significant commercial value of these specialized treatments is highlighted by Ironwood Pharmaceuticals' February 2025 report, which noted that full-year 2024 U.S. net sales for LINZESS alone reached $916.3 million.
Market Challenge
A major hurdle inhibiting the Global Chronic Idiopathic Constipation Therapeutic Market is the extensive patient reliance on dietary supplements and over-the-counter laxatives. This deeply rooted habit of self-medication establishes a significant barrier to prescription therapy adoption, as individuals usually utilize affordable, readily available retail products before seeking professional advice. Consequently, formal diagnoses of Chronic Idiopathic Constipation are often delayed or overlooked, effectively preventing a substantial segment of the potential patient base from accessing advanced, higher-value prescription treatments that generate market revenue.
This hesitation to pursue medical intervention limits the reach of specialized therapeutics, even when severe symptoms warrant professional care. Pharmaceutical manufacturers face difficulties in gaining market share when patients view non-prescription alternatives as sufficient, regardless of their actual long-term effectiveness. For instance, the American College of Gastroenterology reported in a 2024 real-world survey that 95% of patients with constipation-related issues experienced straining during bowel movements, indicating a heavy symptom burden that remains despite self-care attempts. This gap between high symptom severity and persistent dependence on retail solutions curtails the uptake of prescription therapies, directly impeding the market's financial growth.
Market Trends
Pharmaceutical companies are increasingly expanding label indications to include pediatric populations, thereby widening the addressable patient base for chronic idiopathic constipation therapeutics. Manufacturers are securing regulatory approvals to extend the use of established guanylate cyclase-C agonists to adolescents and children, a group previously restricted to osmotic laxatives or off-label treatments. This strategic development targets a significant unmet need within pediatric functional bowel disorders while validating safety profiles for younger users. As reported by Pharmaceutical Technology in November 2025, the FDA approved Linzess for children aged seven and older with irritable bowel syndrome with constipation, effectively expanding the drug's market reach beyond its original adult indications.
Concurrently, the competitive landscape is being reshaped by the introduction of generic prokinetic agents, which are lowering cost barriers. The patent expiration for serotonin-4 receptor agonists has prompted the release of bioequivalent alternatives, making treatments more accessible to patients limited by the high out-of-pocket expenses associated with branded drugs. This availability of lower-cost options enables healthcare providers to prescribe specialized prokinetics more frequently, boosting volume growth in this segment. For example, ANI Pharmaceuticals announced in January 2025 the launch of the first U.S. generic version of Motegrity (prucalopride), targeting a branded market estimated at $168 million annually.
Key Market Players
- GSK PLC
- Astellas Pharma Inc
- Synergy Pharmaceuticals Inc.
- Bayer AG
- Allergan PLC
- Sanofi SA
- Pfizer Inc
- Takeda Pharmaceutical Co Ltd
- Zydus Lifesciences Ltd
- Boehringer Ingelheim GmbH
Report Scope
In this report, the Global Chronic Idiopathic Constipation Therapeutic Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Chronic Idiopathic Constipation Therapeutic Market, By Drug Class
- Bulk-Forming Agents
- Emollients
- Laxatives
- Osmotic Agents
Chronic Idiopathic Constipation Therapeutic Market, By Route of Administration
- Oral
- Parenteral
Chronic Idiopathic Constipation Therapeutic Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Chronic Idiopathic Constipation Therapeutic Market, By Region
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Chronic Idiopathic Constipation Therapeutic Market.
Available Customizations:
Global Chronic Idiopathic Constipation Therapeutic Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
- 1.1. Market Definition
- 1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations
2. Research Methodology
- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations
3. Executive Summary
- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Chronic Idiopathic Constipation Therapeutic Market Outlook
- 5.1. Market Size & Forecast
- 5.1.1. By Value
- 5.2. Market Share & Forecast
- 5.2.1. By Drug Class (Bulk-Forming Agents, Emollients, Laxatives, Osmotic Agents)
- 5.2.2. By Route of Administration (Oral, Parenteral)
- 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
- 5.2.4. By Region
- 5.2.5. By Company (2025)
- 5.3. Market Map
6. North America Chronic Idiopathic Constipation Therapeutic Market Outlook
- 6.1. Market Size & Forecast
- 6.1.1. By Value
- 6.2. Market Share & Forecast
- 6.2.1. By Drug Class
- 6.2.2. By Route of Administration
- 6.2.3. By Distribution Channel
- 6.2.4. By Country
- 6.3. North America: Country Analysis
- 6.3.1. United States Chronic Idiopathic Constipation Therapeutic Market Outlook
- 6.3.1.1. Market Size & Forecast
- 6.3.1.1.1. By Value
- 6.3.1.2. Market Share & Forecast
- 6.3.1.2.1. By Drug Class
- 6.3.1.2.2. By Route of Administration
- 6.3.1.2.3. By Distribution Channel
- 6.3.1.1. Market Size & Forecast
- 6.3.2. Canada Chronic Idiopathic Constipation Therapeutic Market Outlook
- 6.3.2.1. Market Size & Forecast
- 6.3.2.1.1. By Value
- 6.3.2.2. Market Share & Forecast
- 6.3.2.2.1. By Drug Class
- 6.3.2.2.2. By Route of Administration
- 6.3.2.2.3. By Distribution Channel
- 6.3.2.1. Market Size & Forecast
- 6.3.3. Mexico Chronic Idiopathic Constipation Therapeutic Market Outlook
- 6.3.3.1. Market Size & Forecast
- 6.3.3.1.1. By Value
- 6.3.3.2. Market Share & Forecast
- 6.3.3.2.1. By Drug Class
- 6.3.3.2.2. By Route of Administration
- 6.3.3.2.3. By Distribution Channel
- 6.3.3.1. Market Size & Forecast
- 6.3.1. United States Chronic Idiopathic Constipation Therapeutic Market Outlook
7. Europe Chronic Idiopathic Constipation Therapeutic Market Outlook
- 7.1. Market Size & Forecast
- 7.1.1. By Value
- 7.2. Market Share & Forecast
- 7.2.1. By Drug Class
- 7.2.2. By Route of Administration
- 7.2.3. By Distribution Channel
- 7.2.4. By Country
- 7.3. Europe: Country Analysis
- 7.3.1. Germany Chronic Idiopathic Constipation Therapeutic Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.1.1. By Value
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Drug Class
- 7.3.1.2.2. By Route of Administration
- 7.3.1.2.3. By Distribution Channel
- 7.3.1.1. Market Size & Forecast
- 7.3.2. France Chronic Idiopathic Constipation Therapeutic Market Outlook
- 7.3.2.1. Market Size & Forecast
- 7.3.2.1.1. By Value
- 7.3.2.2. Market Share & Forecast
- 7.3.2.2.1. By Drug Class
- 7.3.2.2.2. By Route of Administration
- 7.3.2.2.3. By Distribution Channel
- 7.3.2.1. Market Size & Forecast
- 7.3.3. United Kingdom Chronic Idiopathic Constipation Therapeutic Market Outlook
- 7.3.3.1. Market Size & Forecast
- 7.3.3.1.1. By Value
- 7.3.3.2. Market Share & Forecast
- 7.3.3.2.1. By Drug Class
- 7.3.3.2.2. By Route of Administration
- 7.3.3.2.3. By Distribution Channel
- 7.3.3.1. Market Size & Forecast
- 7.3.4. Italy Chronic Idiopathic Constipation Therapeutic Market Outlook
- 7.3.4.1. Market Size & Forecast
- 7.3.4.1.1. By Value
- 7.3.4.2. Market Share & Forecast
- 7.3.4.2.1. By Drug Class
- 7.3.4.2.2. By Route of Administration
- 7.3.4.2.3. By Distribution Channel
- 7.3.4.1. Market Size & Forecast
- 7.3.5. Spain Chronic Idiopathic Constipation Therapeutic Market Outlook
- 7.3.5.1. Market Size & Forecast
- 7.3.5.1.1. By Value
- 7.3.5.2. Market Share & Forecast
- 7.3.5.2.1. By Drug Class
- 7.3.5.2.2. By Route of Administration
- 7.3.5.2.3. By Distribution Channel
- 7.3.5.1. Market Size & Forecast
- 7.3.1. Germany Chronic Idiopathic Constipation Therapeutic Market Outlook
8. Asia Pacific Chronic Idiopathic Constipation Therapeutic Market Outlook
- 8.1. Market Size & Forecast
- 8.1.1. By Value
- 8.2. Market Share & Forecast
- 8.2.1. By Drug Class
- 8.2.2. By Route of Administration
- 8.2.3. By Distribution Channel
- 8.2.4. By Country
- 8.3. Asia Pacific: Country Analysis
- 8.3.1. China Chronic Idiopathic Constipation Therapeutic Market Outlook
- 8.3.1.1. Market Size & Forecast
- 8.3.1.1.1. By Value
- 8.3.1.2. Market Share & Forecast
- 8.3.1.2.1. By Drug Class
- 8.3.1.2.2. By Route of Administration
- 8.3.1.2.3. By Distribution Channel
- 8.3.1.1. Market Size & Forecast
- 8.3.2. India Chronic Idiopathic Constipation Therapeutic Market Outlook
- 8.3.2.1. Market Size & Forecast
- 8.3.2.1.1. By Value
- 8.3.2.2. Market Share & Forecast
- 8.3.2.2.1. By Drug Class
- 8.3.2.2.2. By Route of Administration
- 8.3.2.2.3. By Distribution Channel
- 8.3.2.1. Market Size & Forecast
- 8.3.3. Japan Chronic Idiopathic Constipation Therapeutic Market Outlook
- 8.3.3.1. Market Size & Forecast
- 8.3.3.1.1. By Value
- 8.3.3.2. Market Share & Forecast
- 8.3.3.2.1. By Drug Class
- 8.3.3.2.2. By Route of Administration
- 8.3.3.2.3. By Distribution Channel
- 8.3.3.1. Market Size & Forecast
- 8.3.4. South Korea Chronic Idiopathic Constipation Therapeutic Market Outlook
- 8.3.4.1. Market Size & Forecast
- 8.3.4.1.1. By Value
- 8.3.4.2. Market Share & Forecast
- 8.3.4.2.1. By Drug Class
- 8.3.4.2.2. By Route of Administration
- 8.3.4.2.3. By Distribution Channel
- 8.3.4.1. Market Size & Forecast
- 8.3.5. Australia Chronic Idiopathic Constipation Therapeutic Market Outlook
- 8.3.5.1. Market Size & Forecast
- 8.3.5.1.1. By Value
- 8.3.5.2. Market Share & Forecast
- 8.3.5.2.1. By Drug Class
- 8.3.5.2.2. By Route of Administration
- 8.3.5.2.3. By Distribution Channel
- 8.3.5.1. Market Size & Forecast
- 8.3.1. China Chronic Idiopathic Constipation Therapeutic Market Outlook
9. Middle East & Africa Chronic Idiopathic Constipation Therapeutic Market Outlook
- 9.1. Market Size & Forecast
- 9.1.1. By Value
- 9.2. Market Share & Forecast
- 9.2.1. By Drug Class
- 9.2.2. By Route of Administration
- 9.2.3. By Distribution Channel
- 9.2.4. By Country
- 9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Chronic Idiopathic Constipation Therapeutic Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.1.1. By Value
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Drug Class
- 9.3.1.2.2. By Route of Administration
- 9.3.1.2.3. By Distribution Channel
- 9.3.1.1. Market Size & Forecast
- 9.3.2. UAE Chronic Idiopathic Constipation Therapeutic Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.1.1. By Value
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Drug Class
- 9.3.2.2.2. By Route of Administration
- 9.3.2.2.3. By Distribution Channel
- 9.3.2.1. Market Size & Forecast
- 9.3.3. South Africa Chronic Idiopathic Constipation Therapeutic Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.1.1. By Value
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Drug Class
- 9.3.3.2.2. By Route of Administration
- 9.3.3.2.3. By Distribution Channel
- 9.3.3.1. Market Size & Forecast
- 9.3.1. Saudi Arabia Chronic Idiopathic Constipation Therapeutic Market Outlook
10. South America Chronic Idiopathic Constipation Therapeutic Market Outlook
- 10.1. Market Size & Forecast
- 10.1.1. By Value
- 10.2. Market Share & Forecast
- 10.2.1. By Drug Class
- 10.2.2. By Route of Administration
- 10.2.3. By Distribution Channel
- 10.2.4. By Country
- 10.3. South America: Country Analysis
- 10.3.1. Brazil Chronic Idiopathic Constipation Therapeutic Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.1.1. By Value
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Drug Class
- 10.3.1.2.2. By Route of Administration
- 10.3.1.2.3. By Distribution Channel
- 10.3.1.1. Market Size & Forecast
- 10.3.2. Colombia Chronic Idiopathic Constipation Therapeutic Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.1.1. By Value
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Drug Class
- 10.3.2.2.2. By Route of Administration
- 10.3.2.2.3. By Distribution Channel
- 10.3.2.1. Market Size & Forecast
- 10.3.3. Argentina Chronic Idiopathic Constipation Therapeutic Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.1.1. By Value
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Drug Class
- 10.3.3.2.2. By Route of Administration
- 10.3.3.2.3. By Distribution Channel
- 10.3.3.1. Market Size & Forecast
- 10.3.1. Brazil Chronic Idiopathic Constipation Therapeutic Market Outlook
11. Market Dynamics
- 11.1. Drivers
- 11.2. Challenges
12. Market Trends & Developments
- 12.1. Merger & Acquisition (If Any)
- 12.2. Product Launches (If Any)
- 12.3. Recent Developments
13. Global Chronic Idiopathic Constipation Therapeutic Market: SWOT Analysis
14. Porter's Five Forces Analysis
- 14.1. Competition in the Industry
- 14.2. Potential of New Entrants
- 14.3. Power of Suppliers
- 14.4. Power of Customers
- 14.5. Threat of Substitute Products
15. Competitive Landscape
- 15.1. GSK PLC
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
- 15.2. Astellas Pharma Inc
- 15.3. Synergy Pharmaceuticals Inc.
- 15.4. Bayer AG
- 15.5. Allergan PLC
- 15.6. Sanofi SA
- 15.7. Pfizer Inc
- 15.8. Takeda Pharmaceutical Co Ltd
- 15.9. Zydus Lifesciences Ltd
- 15.10. Boehringer Ingelheim GmbH
16. Strategic Recommendations
17. About Us & Disclaimer
